Baveno VII algorithm outperformed other models in ruling out high-risk varices in individuals with HBV-related cirrhosis

作者：Zhang, Xiaofeng; Song, Jiankang; Zhang, Yuanjian; Wen, Biao; Dai, Lin; Xi, Ranran; Wu, Qiaoping; Li, Yuan; Luo, Xiaoqin; Lan, Xiaoqin; He, Qinjun; Luo, Wenfan; Lai, Qintao; Ji, Yali; Zhou, Ling; Qi, Tingting; Liu, Miaoxia; Zhou, Fuyuan; Wen, Weiqun; Li, Hui; Liu, Zhihua; Chen, Yongpeng; Zhu, Youfu; Li, Junying; Huang, Jing; Cheng, Xiao; Tu, Minghan; Hou, Jinlin; Wang, Haiyu^*; Chen, Jinjun^*

来源：Journal of Hepatology, 2023, 78(3).

DOI：10.1016/j.jhep.2022.10.030

• Baveno VII
• liver cirrhosis
• high-risk varices
• vibration-controlled transient elastography
• spleen stiffness measurement

Background & Aims: The Baveno VII consensus recommends that spleen stiffness measurement (SSM) <-40 kPa is safe for ruling out high-risk varices (HRVs) and avoiding endoscopic screening in patients who do not meet the Baveno VI criteria. This study aimed to validate the performance of the Baveno VII algorithm in individuals with HBV-related cirrhosis. Methods: Consecutive individuals with HBV-related cirrhosis who underwent liver stiffness measurement (LSM) and SSM - using a 50 Hz shear wave frequency, spleen diameter measurement, and esophagogastroduodenoscopy (EGD) were prospectively enrolled from June 2020. A 100 Hz probe has been adopted for additional SSM assessment since July 2021. Results: From June 2020 to January 2022, 996 patients were screened and 504 were enrolled for analysis. Among the 504 patients in whom SSM was assessed using a 50 Hz probe, the Baveno VII algorithm avoided more EGDs (56.7% vs. 39.1%, p <0.001) than Baveno VI criteria, with a comparable missed HRV rate (3.8% vs. 2.5%). Missed HRV rates were >5% for all other measures: 11.3% for LSM-longitudinal spleen diameter to platelet ratio score, 20.0% for platelet count/longitudinal spleen diameter ratio, and 8.8% for Rete Sicilia Selezione Terapia-hepatitis. SSM@100 Hz was assessed in 232 patients, and the Baveno VII algorithm with SSM@100 Hz spared more EGDs (75.4% vs. 59.5%, p <0.001) than that with SSM@50 Hz, both with a missed HRV rate of 3.0% (1/33). Conclusions: We validated the Baveno VII algorithm, demonstrating the excellent performance of SSM@50 Hz and SSM@100 Hz in ruling out HRV in individuals with HBV-related cirrhosis. Furthermore, the Baveno VII algorithm with SSM@100 Hz could safely rule out more EGDs than that with SSM@50 Hz. Clinical trial number: NCT04890730. (c) 2022 The Author(s). Published by Elsevier B.V. on behalf of European Association for the Study of the Liver. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

• 单位
  1; 南方医科大学